- Details
- Rana McKay and Sumanta (Monty) Pal join Zach Klaassen in discussing the Southern California Genitourinary (GU) Cancer Research Forum, a program aimed at uniting healthcare professionals in Southern California to coordinate research and patient care in GU cancers. The program highlights include discussions on kidney cancer, bladder cancer, and prostate cancer, integrating patient advocates and show...
|
- Details
- The METANOVA Trial investigates treating oligometastatic prostate cancer with metastasis-directed radiotherapy (MDRT) in addition to standard systemic and prostate-directed therapy. MDRT, using targeted radiation on all metastatic sites, aims to extend the time until cancer returns and potentially improve patient survival. Related Content: ClinicalTrials.gov Identifier: NCT06150417 Metastasis-dire...
|
- Details
- ESCAPE Trial design is described in this 3-minute explainer video. The ESCAPE trial is titled Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr and is a study for prostate cancer patients considering active surveillance to delay treatment. Traditionally, PSA tests, biopsies, and MRI scans monitor cancer. How...
|
- Details
- Alicia Morgans interviews Neha Vapiwala about the innovative phase three INDICATE trial, supported by the ECOG-ACRIN Group and NCI designated cooperative groups. The trial focuses on patients with biochemical recurrence after prostatectomy, examining the impact of PET scans on treatment decisions. It categorizes patients based on PET scan results: those without detectable cancer outside the pelvis...
|
- Details
- Zach Klaassen hosts Michael Hofman and Renu Eapen to discuss the LuTectomy trial, published in European Urology. The trial explores the use of Lutetium-PSMA-617 as a neoadjuvant treatment in prostate cancer surgery. Initially, the trial included both radiation and surgical arms, but later focused solely on the surgical approach. The study enrolled high-risk prostate cancer patients, with 20 partic...
|
- Details
- Emmanuel Antonarakis joins Alicia Morgans in a conversation about the trial in progress multicenter, open-label, randomized phase 3 ECLIPSE trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard-of-care hormone therapy in patients with metastatic castration-resistant prostate cancer, previously treated with only one ARAT and are taxane-based chemo naive. The ECLIPSE trial is bei...
|
- Details
- Jones Nauseef speaks with Alicia Morgans about a trial in progress dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA. With the approval of Lutetium 177 Jones Nauseef explains that the study team decided to modify the study design to include a post-177-Lu-PSMA cohort because patie...
|
- Details
- Weill Cornell is leading a randomized Phase II trial of salvage radiation therapy for prostate cancer in four weeks versus five days. The purpose of this trial is to compare the side effects of longer and shorter courses of radiation. Five days of treatment is a new option currently being studied in this trial with real-time MRI guidance. Related Content: ClinicalTrials.gov Identifier: NCT04422132...
|
- Details
- This video presents a study on a novel treatment approach for intermediate risk prostate cancer. The Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE) study investigates the combination of radiation therapy and irreversible electroporation (IRE). Advanced imaging techniques, such as MRI and PSMA PET, help doctors identify aggressive and less aggressiv...
|
- Details
- The NRG-GU 010 phase III trial, known as Guidance, aims to optimize treatment strategies for prostate cancer based on the Decipher risk score. This score evaluates the tumor's potential for spreading, enabling personalized therapy selection. For patients with low risk scores, the trial compares radiation therapy alone to the standard approach of radiation therapy combined with hormone therapy (and...
|
